tiprankstipranks
Trending News
More News >
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
Advertisement

IDEAYA Biosciences (IDYA) AI Stock Analysis

Compare
604 Followers

Top Page

IDYA

IDEAYA Biosciences

(NASDAQ:IDYA)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 4o)
Rating:51Neutral
Price Target:
$25.00
▼(-9.55% Downside)
The overall stock score reflects significant financial challenges, with declining revenues and consistent net losses being the most impactful factors. While technical analysis shows positive trends, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation.
Positive Factors
Strong Equity Position
A strong equity position with minimal leverage provides financial stability and flexibility, enabling the company to invest in R&D and strategic initiatives without excessive debt burden.
Strategic Partnerships
Strategic partnerships offer financial support and access to resources, enhancing drug development capabilities and potentially accelerating commercialization of pipeline products.
Proprietary Drug Discovery Platforms
Proprietary platforms for drug discovery provide a competitive edge in developing targeted therapeutics, potentially leading to breakthrough treatments and long-term growth in the oncology sector.
Negative Factors
Declining Revenue
Significant revenue decline indicates challenges in advancing pipeline products or securing new partnerships, potentially impacting future growth and financial sustainability.
Negative Cash Flow
Negative cash flow from operations suggests ongoing financial strain, requiring the company to secure additional funding to sustain operations and continue R&D efforts.
Profitability Challenges
Persistent profitability challenges highlight operational inefficiencies and the need for strategic improvements to achieve sustainable growth and financial health.

IDEAYA Biosciences (IDYA) vs. SPDR S&P 500 ETF (SPY)

IDEAYA Biosciences Business Overview & Revenue Model

Company DescriptionIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
How the Company Makes MoneyIDEAYA Biosciences generates revenue through a combination of its own product development efforts and strategic partnerships. The company primarily earns money by advancing its pipeline of drug candidates through various stages of clinical trials, leading to potential commercialization. Additionally, IDEAYA enters into collaborations and licensing agreements with larger pharmaceutical companies, which can provide upfront payments, milestone payments based on development progress, and royalties on future sales. These partnerships not only offer financial support but also access to resources and expertise necessary for efficient drug development. The company may also receive funding through grants and investments to support its research initiatives.

IDEAYA Biosciences Financial Statement Overview

Summary
IDEAYA Biosciences is experiencing financial difficulties with declining revenues and consistent net losses. Although it has a strong equity position, the lack of profitability and negative cash flows are significant risks.
Income Statement
42
Neutral
The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.
Balance Sheet
55
Neutral
IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.
Cash Flow
48
Neutral
Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.00M7.00M23.39M50.93M27.94M19.54M
Gross Profit5.26M7.00M19.38M48.83M26.22M-20.16M
EBITDA-357.95M-326.98M-130.42M-60.40M-48.54M-33.96M
Net Income-306.31M-274.48M-112.96M-54.81M-47.53M-32.27M
Balance Sheet
Total Assets1.10B1.12B649.32M387.97M381.35M298.27M
Cash, Cash Equivalents and Short-Term Investments692.51M676.32M525.11M373.15M368.06M283.58M
Total Debt25.97M19.17M2.87M3.48M5.18M6.72M
Total Liabilities76.51M64.94M28.23M387.97M381.35M298.27M
Stockholders Equity1.02B1.06B621.09M349.45M301.51M198.27M
Cash Flow
Free Cash Flow-267.98M-251.44M-117.59M-90.62M-58.42M54.97M
Operating Cash Flow-264.11M-247.58M-115.22M-87.17M-55.78M55.46M
Investing Cash Flow-68.77M-502.56M-158.46M-33.40M-69.67M-146.24M
Financing Cash Flow354.58M677.55M362.72M97.17M145.45M128.75M

IDEAYA Biosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price27.64
Price Trends
50DMA
25.04
Positive
100DMA
23.08
Positive
200DMA
21.89
Positive
Market Momentum
MACD
0.74
Negative
RSI
65.49
Neutral
STOCH
73.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 27.64 is above the 20-day moving average (MA) of 25.73, above the 50-day MA of 25.04, and above the 200-day MA of 21.89, indicating a bullish trend. The MACD of 0.74 indicates Negative momentum. The RSI at 65.49 is Neutral, neither overbought nor oversold. The STOCH value of 73.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Risk Analysis

IDEAYA Biosciences disclosed 77 risk factors in its most recent earnings report. IDEAYA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

IDEAYA Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
$2.32B3.6747.47%30.57%
58
Neutral
$2.55B-26.76-67.11%99.50%65.91%
51
Neutral
$2.40B-35.09%-41.48%-73.55%
50
Neutral
$2.59B-5.71-38.08%-82.90%-155.64%
49
Neutral
$2.16B-12.08-516.25%87.94%57.84%
44
Neutral
$2.10B-14.65-25.61%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IDYA
IDEAYA Biosciences
27.64
-1.77
-6.02%
AGIO
Agios Pharma
40.50
-0.09
-0.22%
TVTX
Travere Therapeutics
24.64
9.38
61.47%
CELC
Celcuity
50.51
35.24
230.78%
ARQT
Arcutis Biotherapeutics
19.92
10.13
103.47%
BEAM
Beam Therapeutics
25.75
2.36
10.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 12, 2025